Marshall Wace’s Day One Biopharmaceuticals DAWN Stock Holding History

Marshall Wace’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.05M	Buy	+328,638	New	+$4.63M	0.01%	1134
2025 Q2	–	Sell	-887,177	Closed	-$7.04M	–	2796
2025 Q1	$7.04M	Sell	887,177 -210,585	-19%	-$2.27M	0.01%	910
2024 Q4	$13.9M	Buy	+1,097,762	New	+$15.3M	0.02%	675
2024 Q3	–	Sell	-161,129	Closed	-$2.22M	–	2588
2024 Q2	$2.22M	Buy	161,129 +26,958	+20%	+$394K	﹤0.01%	1313
2024 Q1	$2.22M	Buy	134,171 +16,277	+14%	+$244K	﹤0.01%	1316
2023 Q4	$1.72M	Sell	117,894 -343,941	-74%	-$4.17M	﹤0.01%	1284
2023 Q3	$5.67M	Sell	461,835 -327,797	-42%	-$4.28M	0.01%	828
2023 Q2	$9.43M	Buy	+789,632	New	+$10.3M	0.02%	760
2022 Q3	–	Sell	-145,898	Closed	-$2.61M	–	3415
2022 Q2	$2.61M	Buy	145,898 +128,155	+722%	+$1.32M	0.01%	1801
2022 Q1	$176K	Buy	+17,743	New	+$234K	﹤0.01%	3127

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Marshall Wace's DAWN Position: Q1 2026 in Review

Marshall Wace opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 328,638 shares worth $7.05M. The stake represents 0.01% of the portfolio and ranks #1134 among its holdings. This is a return to the name: Marshall Wace previously reported a position in DAWN as recently as Q1 2025.

Marshall Wace first reported a position in DAWN in Q1 2022 and has held it in 10 quarters since. The position peaked at $13.9M in Q4 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Marshall Wace held 328,638 shares of Day One Biopharmaceuticals worth $7.05M as of Q1 2026.
Day One Biopharmaceuticals was a new Marshall Wace position in Q1 2026.
Day One Biopharmaceuticals made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1134 holding.
Marshall Wace first reported a position in Day One Biopharmaceuticals in Q1 2022 and has held it in 10 quarters since.
Marshall Wace's Day One Biopharmaceuticals position peaked at $13.9M in Q4 2024.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.